Cell cycle regulatory proteins in renal disease: Role in hypertrophy, proliferation, and apoptosis

American Journal of Physiology - Renal Physiology

Volumn 278, Issue 4 47-4, 2000, Pages

  Shankland, Stuart J ^a,c   Wolf, Gunter ^b  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF HAMBURG   (Germany)

^c UNIVERSITY OF WASHINGTON MEDICAL CENTER   (United States)

Author keywords

Cell cycle; Cyclin; Glomerulus; Kidney; Mesangial cell

Indexed keywords

CYCLIN DEPENDENT KINASE; CYCLIN DEPENDENT KINASE INHIBITOR; CYCLINE;

APOPTOSIS; CELL PROLIFERATION; HUMAN; HYPERTROPHY; KIDNEY DISEASE; NONHUMAN; PRIORITY JOURNAL; REVIEW;

EID: 0034004155     PISSN: 1931857X     EISSN: 15221466     Source Type: Journal    
DOI: 10.1152/ajprenal.2000.278.4.f515     Document Type: Review

References (155)

1. Abboud HE. Growth factors in glomerulonephritis. Kidney Int 43: 252-267, 1993.
2. Addis T and Oliver J. The Renal Lesion in Bright's Disease. New York: Hoeber, 1931.
3. Akashi M, Osawa Y, Koeffler HP, and Hachiya M. Acad Emerg Med p53: important role of RNA stabilization. Biochemistry 337: 607-616, 1999.
4. WAF/CIPI is required for glomerular hypertrophy in experimental diabetic nephropathy. Kidney Int 56: 1691-1699, 1999.
5. Baker AJ, Mooney A, Hughes J, Lombardi D, Johnson RJ, and Savill J. Mesangial cell apoptosis: the major mechanism for resolution of glomerular hypercellularity in experimental mesangial proliferative nephritis. J Clin Invest 94: 2105-2116, 1994.
6. Baldin V, Lukas J, Marcote MJ, Pagano M, and Draetta G. Cyclin D1 is a protein required for cell cycle progression in G1. Genes Dev 7: 812-821, 1993.
7. Brugarolas J, Chandrasekaran C, Gordon JI, Beach D, Jacks T, and Hannon GJ. Radiation-induced cell cycle arrest comprimised by p21-deficiency. Nature 377: 552-557, 1995.
8. Buchkovich K, Duffy LA, and Harlow E. The retinoblastoma protein is phosphorylated during specific phases of the cell cycle. Cell 58: 1097-1105, 1989.
9. Choi ME, Eung-Gook K, Huang Q, and Ballerman BJ. Rat mesangial cell hypertrophy in response to transforming growth factor-β1. Kidney Int 44: 948-958, 1993.
10. Conion I and Raff M. Size control in animal development. Cell 96: 235-244, 1999.
11. kip1, in developeing and mature human kidney. Kidney Int 53: 892-896, 1998.
12. Cordon-Cardo C. Mutation of cell cycle regulators. Biological and clinical implications for human neoplasia. Am J Pathol 147: 545-560, 1995.
13. Cosio FG. Effects of high glucose concentrations on human mesangial cell proliferation. J Am Soc Nephrol 5: 1600-1609, 1995.
14. D'Agati V. The many masks of focal segmental glomerulosclerosis. Kidney Int 46: 1223-1241, 1994.
15. DeBondt HL, Rosenblatt J, Jancarik J, Jons HD, and Morgon DO. Crystal structure of cyclin dependent kinase 2. Nature 363: 595-602, 1993.
16. Draetta B. cdc2 activation: the interplay of cyclin binding and Thr161 phosphorylation. Trends Cell Biol 3: 287-289, 1993.
17. Draetta G and Beach D. Activation of cdc2 protein kinase during mitosis in human cells: cell cycle-dependent phosphorylation and subunit rearrangement. Cell 54: 17-26, 1988.
18. El-Deiry WS, Tokino T, Velculescu VE, Levy DB, Parsons R, Trent JM, Lin D, Mercer WE, Kinzler KW, and Vogelstein B. p21WAF1, a potential mediator of p53 tumor suppression. Cell 75: 817-825, 1993.
19. Elbendary A, Berchuck A, Davis P, Havrilesky L, Bast RC, Iglehart D, and Marks JR. Transforming growth factor β1 can induce CIP1/WAF1 expression independent of the p53 pathway in ovarian cancer cells. Cell Growth Differ 5: 1301-1307, 1994.
20. Elledge SJ, and Harper JW. CDK inhibitors: on the threshold of checkpoints and development. Curr Opin Cell Biol 6: 847-852, 1994.
21. Fine LG. The biology of renal hypertrophy. Kidney Int 29: 619-634, 1986.
22. Fine LG and Norman J. Cellular events in renal hypertrophy. Annu Rev Physiol 51: 19-32, 1989.
23. Floege J, Kriz W, Schulze M, Susani M, Kerjaschki D, Mooney A, Couser WG, and Koch KM. Basic fibroblast growth factor augments podocyte injury and induces glomerulosclerosis in rats with experimental membranous nephrology. J Clin Invest 96: 2809-2819, 1996.
24. Fogo A, Hawkins EP, Berry PL, Glick AD, Chiang ML, MacDonell RC, and Ichikawa I. Glomerular hypertrophy in minimal change disease predicts subsequent progression to focal glomerular sclerosis. Kidney Int 38: 115-123, 1990.
25. Franch HA, Alpern RJ, and Preisig PA. Alkalmization of acidic vesicular compartments induces hypertrophy in the absence of cell entry (Abstract). J Am Soc Nephrol 5: 692, 1994.
26. Franch HA, Alpern RJ, and Preisig PA. TGFβ converts EGF-induced hyperplasia to hypertrophy by inhibiting CDK2/ cyclin E kinase activity (Abstract). J Am Soc Nephrol 6: 767, 1995.
27. Fries JLW, Sandstrom DJ, Meyer TW, and Rennke HG. Glomerular hypertrophy and epithelial cell injury modulate progressive glomerulosclerosis in the rat. Lab Invest 60: 205-218, 1989.
28. Geng Y, and Weinberg RA. Transforming growth factor β effects on expression of G1 cyclins and cyclin-dependent kinases. Proc Natl Acad Sci USA 90: 10315-10319, 1993.
29. Girard F, Strausfeld U, Fernandez A, and Lamb N. Cyclin A is required for the onset of DNA replication in mammalian fibroblasts. Cell 67: 1169-1179, 1991.
30. Glotzer M. The mechanism and control of cytokinesis. Curr Opin Cell Biol 9: 815-823, 1997.
31. Grana X, and Reddy EP. Cell cycle control in mammalian cells: role of cyclins, cyclin-dependent kinases (CDKs), growth suppressor genes and cyclin-dependent kinase inhibitors (CKIs). Oncogene 11: 211-219, 1995.
32. Gudas JM, Payton S, Thukras S, Chen E, Mass M, Robinson MO, and Coats S. Cyclin E2, a novel G1 cyclin that binds CDK2 and is aberrantly expressed in human cancers. Mol Cell Biol 19: 612-622, 1999.
33. Hakem A, Sasaki T, Kozieradzki I, and Perininger JM.. The cyclin-dependent kinase CDK2 regulates thymocyte apoptosis. J Exp Med 189: 957-967, 1999.
34. Hammerman MR. Growth factors and apoptosis in acute renal injury. Curr Opin Nephrol Hypertens 7: 419-424, 1998.
35. Hannken T, Schroeder R, Stahl RAK, and Wolf G. Angiotensin II-mediated expression of p27(Kip1) and induction of cellular hypertrophy in renal tubular cells depend on the generation of oxygen radicals. Kidney Int 54: 1923-1933, 1998.
36. Hara E, Smith R, Parry D, Tahara H, Stone S, and Peters G. Regulation of p16(CDKN2) expression and its implication for cell immortalization and senescence. Mol Cell Biol 16: 859-867, 1996.
37. Hattori T, Shindo S, and Kawamura H. Apoptosis and expression of Bax protein and Fas antigen in glomeruli of a remnant-kidney model. Nephron 79: 186-191, 1998.
38. Cip1. Genes Dev 12: 3882-3888, 1998.
39. Hengst L, and Reed SI. Inhibitors of the Cip/Kip family. Curr Top Microbiol Immunol 227: 25-41, 1998.
40. Kip1. J Clin Invest 103: 597-604, 1999.
41. Hirschberg R and Ding H. Growth factors and acute renal failure. Semin Nephrol 18: 191-207, 1998.
42. Hostetter TH. Progression of renal disease and renal hypertrophy. Annu Rev Physiol 57: 263-278, 1995.
43. Huang H and Wang H. Cyclin D1, CDK4 expression and cyclin D1 upregulation by endothelin-1 in rat mesangial cells (Abstract). J Am Soc Nephrol 7: 1658, 1996.
44. Huang HC and Preisig P. Cyclin D kinase is activated in all diabetic renal growth, while cyclin E kinase determines whether the growth pattern will be by hyperplasia or hypertrophy (Abstract). J Am Soc Nephrol 9: A2252, 1998.
45. CIP1/WAF1 limits interstitial but not tubular cell proliferation after ureteric obstruction. Am J Physiol Renal Physiol 277: F948-F956, 1999.
46. Inoshita S, Terada Y, Ymamda T, Nakashima O, Sasaki S, and Marumo F. Mitogenic signaling of endothelin-1 is regulated by cyclin D1, p16 and the phosphorylation of retinoblastoma gene product in rat mesangial cells (Abstract). J Am Soc Nephrol 7: 1564, 1996.
47. Johnson J. The glomerular response to injury: progression or resolution? Kidney Int 45: 1769-1782, 1994.
48. Kato J and Sherr J. Inhibition of granulocyte differentiation by G1 cyclins D2 and D3 but not D1 C. Proc Natl Acad Sci USA 90: 11513-11517, 1993.
49. Kim Y-G, Alpers CE, Brugarolas J, Johnson RJ, Couser WG, and Shankland SJ. The cyclin kinase inhibitor p21Cip1/ WAF1 limits glomerular epithelial cell proliferation in experimental glomerulonephritis. Kidney Int 55: 2349-2361, 1999.
50. Klahr S, Schreiner G, and Ichikawa I. Progression in renal disease. N Engl J Med 318: 1657-1666, 1988.
51. Kreisberg JI, and Ayo SH. The glomerular mesangium in diabetes mellitus. Kidney Int 43: 109-113, 1993.
52. Kreisberg JI, Radnik RA, Ayo SH, Garoni J, and Saikumar P. High glucose elevates c-fos and c-jun transcripts and proteins in mesangial cell cultures. Kidney Int 46: 105-112, 1994.
53. Kriz W. Progressive renal failure - inability of podocytes to replicate and the consequences for development of glomerulosclerosis. Neprhol Dial Transplant 11: 1738-1742, 1996.
54. Kriz W, Gretz N, and Lemley KV. Progression of glomerular diseases: is the podocyte the culprit? Kidney Int 54: 687-687, 1998.
55. Kriz W, Hahnel B, Rosener S, and Elger M. Long-term treatment of rats with FGF-2 results in focal segmental glomerulosclerosis. Kidney Int 48: 1435-1450, 1995.
56. WAF1, CIP1 is increased in experimental diabetic nephropathy: potential role in glomerular hypertrophy. J Am Soc Nephrol 9: 986-993, 1998.
57. Lees E. Cyclin dependent kinase regulation. Curr Opin Cell Biol 7: 773-780, 1995.
58. Levkau B, Koyama H, Raines EW, Clurman BE, Herren B, Orth K, Roberts JM, and Ross R. Cleavage of p21 (Cip1/ Waf1) and p27 (Kip1) mediates apoptosis in endothelial cells through activation of CDK2: role of a caspase cascade. Mol Cell 1: 553-563, 1998.
59. Lieberthal W, and Levine JS. Mechanisms of apoptosis and its potential role in renal tubular epithelial cell injury. Am J Physiol Renal Fluid Electrolyte Physiol 271: F477-F488, 1996.
60. Liu B and Preisig P. Compensatory renal hypertrophy (CRH) is mediated by both cell cycle-dependent and -independent growth processes (Abstract). J Am Soc Nephrol 9: 444A, 1998.
61. Liu B and Preisig P. Renal hypertrophy following uninephrectomy (Unx) is associated with activation of CDK2-cyclin E, but not CDK4/cyclin D1 kinase (Abstract). J Am Soc Nephrol 8: A1966, 1997.
62. Megyesi J, Safirstein R L, and Price P M. Induction of p21WAF1/CIP1/SDI1 in kidney tubule cells affects the course of cisplatin-induced acute renal failure. J Clin Invest 101: 777-82, 1998.
63. Megyesi J, Udvarhelyi N, Safirstein RL, and Price PM. The p53-independent activation of transcription of p21WAF1/ CIP1/SDI1 after acute renal failure. Am J Physiol Renal Fluid Electrolyte Physiol 271: F1211-F1216, 1996.
64. Meikrantz W and Senegal R. Apoptosis and the cell cycle. J Cell Biochem 58: 160-174, 1995.
65. Morgan DO. Principles of CDK regulation. Nature 374: 131-134, 1995.
66. Morrissey JJ, Ishidoya S, McCracken R, and Klahr S. Control of p53 and p21 (WAF1) expression during unilateral ureteral obstruction. Kidney Int 50: S84-S92, 1996.
67. Morrissey JJ, Ishidoya S, McCracken R, and Klahr S. The effect of ACE inhibitors on the expression of matrix genes and the role of p53 and p21 (WAF1) in experimental renal fibrosis. Kidney Int 49, Suppl 54: S83-S87, 1996.
68. Muda AO, Feriozzi S, Cinotti GA, and Faraggiana T. Glomerular hypertrophy and chronic renal failure in focal segmental glomerulosclerosis. Am J Kidney Dis 23: 237-241, 1994.
69. Murray A. Cyclin ubiquitination: the destructive end of mitosis. Cell 81: 149-152, 1995.
70. Murray A and Hunt T. The Cell Cycle. An Introduction. New York: Oxford Univ. Press, 1993.
71. Nagata M, Nakayama K, Terada Y, Hoshi S, and Watanabe T. Cell cycle regulation and differentiation in the human podocyte lineage. Am J Pathol 153: 1511-1520, 1998.
72. Nasmyth K. Viewpoint: putting the cell cycle in order. Science 274: 1643-1645, 1996.
73. Nguyen H, Gitig DM, and Koff A. Cell-free degradation of p27(Kip1), a G1 cyclin-dependent kinase inhibitor, is dependent on CDK2 activity and the proteasome. Mol Cell Biol 19: 1190-1201, 1999.
74. Norbury C and Nurse P. Animal cell cycles and their control. Annu Rev Biochem 61: 441-471, 1992.
75. Nourse J, Firpo E, Flanagan WM, Coats S, Polyak K, Lee M, Massague J, Crabtree GR, and Roberts JM. Interleukin-2-mediated elimination of the p27kip1 cyclin-dependent kinase inhibitor prevented by rapamycin. Nature 372: 570-573, 1994.
76. Nurse P. Universal control mechanism regulating onset of M-phase. Nature 344: 503-508, 1990.
77. Ohtsubo M and Roberts M. Cyclin-dependent regulation of G1 in mammalian fibroblasts. Science 259: 1908-1912, 1993.
78. 1-to-S phase transition. Mol Cell Biol 15: 2612-2624, 1995.
79. Okado T, Terada Y, Inoshita S, Nakashima O, Kuwahara M, Sasaki S, and Marumo F. Glucorticoids stimulate p21(Cip1) gene promoter activity and inhibit mesangial cell cycle: involvement of C/EBPalpha in transcription oif p21(Cip1) (Abstract). J Am Soc Nephrol 9: 444A, 1998.
80. Kip1 safegaurds against inflammatory injury. Nat Med 4: 575-580, 1998.
81. Pabst R and Sterzel B. Cell renewal of glomerular cell types in normal rats R. An autoradiographic analysis. Kidney Int 24: 626-631., 1983.
82. Pagano M, pepperkok R, Verde F, Ansorge W, and Draetta G. Cyclin A is required at two points in the human cell cycle. EMBO J 11: 961-971, 1992.
83. Pagtalunan ME, Miller PL, Jumping-Eagle S, Nelson RG, Myer BD, Rennke HG, Coplon NS, Sun L, and Meyer TW. Podocyte loss and progressive glomerular injury in type II diabetes. J Clin Invest 99: 342-348, 1997.
84. Pardee B. G1 events and regulation of cell proliferation A. Science 246: 603-608, 1989.
85. Park SK, Kang SK, Lee DY, Kang MJ, Kim SH, and Koh GY. Temporal expression of cyclins and cyclin-dependent kinases during renal development and compensatory growth. Kidney Int 51: 762-769, 1997.
86. Pavenstadt H. The podocyte-a neglected player in glomerular injury? Nephrol Dial Transplant 10: 147-161, 1995.
87. Peter M and Herskowitz I. Joining the complex: cyclin-dependent kinase inhibitory proteins and the cell cycle. Cell 79: 181-184, 1994.
88. Pippin JW, Qu Q, Meijer L, and Shankland SJ. Direct in vivo inhibition of the nuclear cell cycle cascade in experimental mesangial proliferative glomerulonephritis with roscovitine, a novel cyclin-dependent kinase antagonist. J Clin Invest 100: 2512-2520, 1997.
89. Piwnica-Worms H. Reversible phosphorylation and mitotic control. J Lab Clin Med 128: 350-354, 1996.
90. Preisig P A, and Franch H A. Renal epithelial cell hyperplasia and hypertrophy. Semin Nephrol 15: 327-340, 1995.
91. Preisig PA, and Franch HA. Renal epithelial hyperplasia and hypertrophy. Semin Nephrol 15: 327-340., 1995.
92. Prescott LF. The normal urinary excretion rates of renal tubular cells, leukocytes, and red blood cells. Clin Sci (Colch) 31: 425-435, 1966.
93. Rabkin R, and Fervenza F C. Renal hypertrophy and kidney disease in diabetes. Diabetes Metab Rev 12: 217-241, 1996.
94. Rennke HG. How does glomerular epithelial cell injury contribute to progressive glomerular damage? Kidney Int 45: S58-S63, 1994.
95. Reynisdottir I, Polyak K, Iavarone A, and Massague J. Kip/Cip and INK4 CDK inhibitors cooperate to induce cell cycle arrest in response to TGFbeta. Genes Dev 9: 1831-1845, 1995.
96. Riley DJ, Lee EY-HP, and Lee W-H. The retinoblastoma protein: more than a tumor suppressor. Annu Rev Cell Biol 10: 1-29, 1994.
97. Riley DJ, Nikitin AY, Frank MA, and Lee W-H. Control of mesangial cell proliferation by conditional expression of a retinoblastoma transgene (Abstract). J Am Soc Nephrol 9: 445A, 1998.
98. Safirstein R. Gene expression in nephrotoxic and ischemic acute renal injury. J Am Soc Nephrol 4: 1387-1395, 1994.
99. Savill J. Apoptosis in resolution of inflammation. J Leukoc Biol 61: 375-380, 1997.
100. Schoecklmann HO, Rupprecht HD, Zauner I, and Sterzel RB. TGFbeta-1-induced cell cycle arrest in renal mesangial cells involves inhibition of cyclin E-CDK2 activation and retinoblastoma protein phosphorylation. Kidney Int 51: 1228-1236, 1997.
101. Shankland SJ. Cell cycle control and renal disease. Kidney Int 52: 294-308, 1997.
102. Kip1 in renal disease. Kidney Int 54: 2241-2242, 1998.
103. Shankland SJ, Floege J, Thomas SE, Nangaku M, Hugo C, Pippin J, Henne K, Hockenberry DM, Johnson RJ, and Couser WG. Cyclin kinase inhibitors are increased during experimental membranous nephropathy: potential role in limiting glomerular epithelial cell proliferation in vivo. Kidney Int 52: 404-413, 1997.
104. Shankland SJ, Hamel PA, and Scholey JW. Phosphorylation of retinoblastoma protein in glomeruli of normal, diabetic and renal-ablated rats (Abstract). J Am Soc Nephrol 5: 701, 1994.
105. Shankland SJ, Hamel PA, and Scholey JW. Cyclin and cyclin dependent kinase expression in the remnant glomerulus. J Am Soc Nephrol 8: 368-375, 1996.
106. Shankland SJ, Hugo C, Coats SR, Nangaku M, Pichler RH, Gordon KL, Pippin J, Roberts JM, Couser WG, and Johnson RJ. Changes in cell cycle protein expression during experimental mesangial proliferative glomerulonephritis. Kidney Int 50: 1230-1239, 1996.
107. Shankland SJ, Pippin J, Flanagan M, Coats SR, Nangaku M, Gordon KL, Roberts JM, Couser WG, and Johnson RJ. Mesangial cell proliferation mediated by PDGF and bFGF is determined by levels of the cyclin kinase inhibitor p27Kip1. Kidney Int 51: 1088-1099, 1997.
108. Shankland SJ and Scholey JW. Expression of growth-related protooncogenes during diabetic renal hypertrophy. Kidney Int 47: 782-788, 1995.
109. Shankland SJ and Scholey JW. Expression of transforming growth factor-β1 during diabetic renal hypertrophy. Kidney Int 46: 430-442, 1994.
110. Sharma K, Jin Y, Guo J, and Ziyadeh FN. Neutralization of TGF-β by anti-TGF-β antibody attenuates kidney hypertrophy and enhanced extracellular mtrix gene expression in STZ-induced diabetic mice. Diabetes 45: 522-530, 1996.
111. Sheaff RJ, Groudine M, Gordon M, Roberts JM, and Clurman BE. Cyclin E-CDK2 is a regulator of p27(Kip1). Genes Dev 11: 1464-1478, 1997.
112. Sherr J. G1 phase progression: cycling on cue C. Cell 79: 551-555, 1994.
113. Sherr J. Mammalian G1 cyclins C. Cell 73: 1059-1065, 1993.
114. Sherr CJ. Mammalian G1 cyclins. Cell 73: 1059-1065, 1993.
115. Sherr CJ and Roberts JM. Inhibitors of mammalian G1 cyclin-dependent kinases. Genes Dev 9: 1149-1163, 1995.
116. Sherr C J, and Roberts J M. Inhibitors of mammalian G1 cyclin-dependent kinases. Genes Dev 9: 1149-1163, 1995.
117. Shimizu A, Kitamura H, Masuda Y, Ishizaki M, Sugisaki Y, and Yamanaka N. Rare glomerular capillary regeneration and subsequent capillary regression with endothelial cell apoptosis in progressive glomerulonephritis. Am J Pathol 151: 1231-1239, 1997.
118. Solomon MJ and Kaldis P. Regulation of CDKs by phosphorylation. In: Cell Cycle Controls, edited by M. Pagano. Berlin: Springer, 1998.
119. Sterzel RB, Schulze-Lohoff E, and Marx M. Cytokines and mesangial cells. Kidney Int 39: 26-31, 1993.
120. Tenschert S, Elger M, and Lemley KV. Glomerular hypertrophy afer subtotal nephrectomy: relationship to early glomerular injury. Virchows Arch 426: 509-517, 1995.
121. Terada Y, Inoshita S, Nakashima O, Kuwahara M, Sasaki S, and Marumo F. Cyclins and cyclin-kinase system-their roles in nephrology. Nephrol Dial transplant 13: 1913-1916, 1998.
122. Terada Y, Inoshita S, Nakashima O, Yamada T, Kuwahara M, Sasaki S, and Marumo F. Lovastin inhibits mesangial cell proliferation via p27 (Kip1) (Abstract). J Am Soc Nephrol 9: 2235-2243, 1998.
123. Terada Y, Nakashima O, Inoshita S, Yamada T, Sasaki S, and Marumo F. Overexpression of cell cycle inhibitors [p27(Kip1) and p21(Cip1)] using adenovirus vector causes hypertrophy in LLC-PK(1) cells (Abstract). J Am Soc Nephrol 8: A1989, 1997.
124. Terada Y, Yamada T, Nakashima O, Sasaki S, and Marumo F. Angiotensin II induced p21CIP1 via JAK2-STAT1 pathway and caused hypertrophy in proximal tubule cells (Abstract). J Am Soc Nephrol 7: 1776, 1996.
125. Terada Y, Yamada T, Nakashima O, Tamamori M, Ito H, Sasaki S, and Marumo F. Overexpression of cell cycle inhibitors (p16INK4 and p21Cip1) and cyclin D1 using adenovirus vectors regulates proliferation of rat mesangial cells. J Am Soc Nephrol 8: 51-60, 1997.
126. Thomas SE, Anderson S, Gordon KL, Oyama TT, Shankland SJ, and Johnson RJ. Tubulointerstitial disease in aging: evidence for underlying peritubular capillary damage, a potential role for renal ischemia. J Am Soc Nephrol 9: 231-242, 1998.
127. Tiefenbrun N, Melamed D, Levy N, Resnitzky D, Hoffman I, Reed SI, and Kimchi A. Alpha interferon suppresses the cyclin D3 and cdc25A genes, leading to a reversible G0-like arrest. Mol Cell Biol 16: 3934-3944, 1996.
128. Toback FG. Regeneration after acute tubular necrosis. Kidney Int 41: 226-246, 1992.
129. Toth T and Takebayashi S. Glomerular hypertrophy in relapsing minimal change nephropathy. Nephron 74: 64-71, 1996.
130. Toyoshima H and Hunter T. p27, a novel inhibitor of G1 cyclin-Cdk protein kinase activity, is related to p21. Cell 78: 67-74, 1994.
131. Truong LD, Sheikh-Hamad D, Chakraborty S, and Suki WN. Cell apoptosis and proliferation in obstructive uropathy. Semin Nephrol 18: 641-651, 1998.
132. Waga S, Hannon HJ, Beach D, and Stillman B. The p21 inhibitor of cyclin-dependent kinases controls DNA replication by interaction with PCNA. Nature 369: 574-578, 1994.
133. Weinberg A. The retinoblastoma protein and the cell cycle R. Cell 81: 323-330, 1995.
134. Wolf G. Cellular mechanisms of tubule hypertrophy and hyperplasia in renal injury. Miner Electrolyte Metab 21: 303-316, 1995.
135. Wolf G. Changing concepts of compensatory renal growth: from humoral pathology to molecular biology. Am J Nephrol 12: 369-373, 1992.
136. Wolf G. Regulating factors of renal tubular hypertrophy. Clin Invest Med 71: 867-870, 1993.
137. Wolf G, Heeger PS, and Neilson EG. Proto-oncogenes as targets of hormone and growth factor actions in the kidney. Contemp Issues Nephrol 23: 111-139, 1991.
138. Wolf G, Mueller E, Stahl RAK, and Ziyadeh FN. Angiotensin II-induced hypertrophy of cultured murine proximal tubular cells is mediated by endogenous transforming growth factor beta. J Clin Invest 92: 1366-1372, 1993.
139. Wolf G, and Neilson EG. Angiotensin II induces cellular hypertrophy in cultured murine proximal tubular cells. Am J Physiol Renal Fluid Electrolyte Physiol 259: F768-F777, 1990.
140. Wolf G, Schroeder R, Thaiss F, Ziyadeh FN, Helmchen U, and Stahl RAK. Glomerular expression of p27Kip1 in diabetic db/db mouse: role of hyperglycemia. Kidney Int 53: 869-879., 1998.
141. Wolf G, Schroeder R, Ziyadeh FN, Thaiss F, Zahner G, and Stahl RAK. High glucose stimulates expression of p27Kip1 in cultured mouse mesangial cells:relationship to hypertrophy. Am J Physiol Renal Physiol 273: F348-F356, 1997.
142. Wolf G, Sharma K, Chen Y, Ericksen M, and Ziyadeh FN. High glucose-induced proliferation in mesangial cells is reversed by autocrine TGF-β. Kidney Int 42: 647-656, 1992.
143. Wolf G, and Stahl RAK. Angiotensin II-stimulated hypertrophy of LLC-PK1 cells depends on the induction of the cyclin dependent kinase inhibitor p27Kip1. Kidney Int 50: 2112-2119, 1996.
144. Wolf G, and Ziyadeh FN. Molecular mechanisms of diabetic renal hypertrophy. Kidney Int 56: 393-405, 1999.
145. Wolf GF, and Neilson EG. Molecular mechanisms of tubuloin-terstitial hypertrophy and hyperplasia. Kidney Int 39: 401-420, 1991.
146. Yamada T, Terada Y, Nakashima O, Sasaki S, and Marumo F. Regulation of G1 cyclin and cell cycle inhibitors in experimental glomerulonephritis (Abstract). J Am Soc Nephrol 7: 1726, 1996.
147. Yamada T, Terada Y, Shimizu A, Sasaki Yamanaka N, and Murumo F. Regulations of G1 cyclin and cell cycle inhibitors during recovery from acute renal ischemia (Abstract). J Am Soc Nephrol 6: 992, 1995.
148. Yamamoto T, Nakamura T, Noble NA, Ruoslahti E, and Border WA. Expression of transforming growth factor β is elevated in human and experimental diabetic nephropathy. Proc Natl Acad Sci USA 90: 1814-1818, 1993.
149. Young BA, Johnson RJ, Alpers CE, Eng E, Gordon K, Floege J, Couser WG, and Seidel K. Cellular events in the evolution of experimental diabetic nephropathy. Kidney Int 47: 935-944, 1995.
150. Zariwala M and Xiong Y. Lack of mutations in the cyclin-dependent kinase inhibitor, p19(INK4d), in tumor-derived cell lines and primary tumors. Oncogene 13: 2033-2038, 1996.
151. Zatz R, and Fujihara CK. Glomerular hypertrophy and progressive glomerulopathy Is there a definite pathogenetic correlation? Kidney Int 45: S-27-S-29, 1994.
152. Zhang H, Xiong Y, and Beach D. Proliferating cell nuclear antigen and p21 are components of multiple cell cycle kinase complexes. Mol Biol Cell 4: 897-906, 1993.
153. Zhang P, Liegeois NJ, Wong C, Finegold M, Hou H, Thompson JC, Silverman A, Harper JW, DePinho RA, and Elledge SJ. Altered cell differentiation and proliferation in mice lacking p57Kip2 indicates a role in Beckwith-Wiedermann syndrome. Nature 387: 151-158, 1997.
154. Zhang P, Wong C, DePinho RA, Harper JW, and Elledge SJ. Cooperation between the CDK inhibitors p27(Kip1) and p57(Kip2) in the control of tissue growth and development (Abstract). Genes Dev 12, 1998.
155. Ziyadeh FN and Sharma K. Role of transforming growth factor-β in diabetic glomerulosclerosis and renal hypertrophy. Kidney Int 48: S34-S36, 1995.